Evidence map›Paper›PMID 41567204›Full record

ArticleFrontiers in immunology2025

Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.

Shifa Zhang, Anhao Hu, Jiuhe Sun, Yutao Wei, Jishan Zhang, Haibo Cai, Gongchao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shifa ZhangDepartment of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Anhao HuDepartment of Clinical Medicine, Jining Medical University, Jining, China.
Jiuhe SunDepartment of Thoracic Surgery, Jining No.1 People's Hospital, Affiliated Jining No.1 People's Hospital of Jining Medical University, Jining, Shandong, China.
Yutao WeiDepartment of Thoracic Surgery, Jining No.1 People's Hospital, Affiliated Jining No.1 People's Hospital of Jining Medical University, Jining, Shandong, China.
Jishan ZhangDepartment of Clinical Medicine, Jining Medical University, Jining, China.
Haibo CaiDepartment of Thoracic Surgery, Jining No.1 People's Hospital, Affiliated Jining No.1 People's Hospital of Jining Medical University, Jining, Shandong, China.
Gongchao WangDepartment of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study compared the efficacy of neoadjuvant immunochemotherapy (nICT) followed by surgery versus upfront surgery for locally advanced esophageal squamous cell carcinoma (ESCC). Methods: In this prospective controlled trial (2020-2025), 623 stage II-IIIB ESCC patients were included; 192 received nICT (cisplatin, nab-paclitaxel, sintilimab) before surgery, and 431 underwent direct surgery. Propensity-score matching (PSM) and overlap weighting were used to adjust for baseline confounders. Results: After PSM (144 pairs), the nICT group showed significantly improved progression-free survival (PFS; HR = 0.31, p<0.001) and overall survival (OS; HR = 0.42, p=0.002) compared to the upfront surgery group. The nICT group also had higher 1-/3-year PFS (88.8%/84.3% vs. 68.1%/52.8%) and OS rates (94.8%/84.7% vs. 89.6%/65.2%). Sensitivity analysis using overlap weighting confirmed these robust findings (PFS: HR = 0.37, p<0.001; OS: HR = 0.62, p=0.033). Conclusions: For locally advanced ESCC, neoadjuvant immunochemotherapy significantly improves both PFS and OS compared to upfront surgery, establishing it as a highly effective treatment strategy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyAgedAntibodies, Monoclonal, HumanizedCisplatinFemaleHumansMaleMiddle AgedNeoplasm StagingPropensity ScoreProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedCisplatinesophageal squamous cell carcinomaneoadjuvant immunochemotherapyoverall survivalPD-1 blockadeprogression-free survivalpropensity-score matching

Identifiers

PMID41567204
PMCPMC12816230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.